News
INVO Bioscience Highlights INVOcell Progress From the 2022 American Society for Reproductive Medicine (ASRM) Congress & Expo
- The multi-billion-dollar global fertility market is predicted to reach approximately US$47.9 billion by 2030, yet remains severely underserved with many patients (upwards of 90% by many estimates) unable to access affordable treatment. - The INVOcell solution...
INVOcell Review Published in Current Opinion in Obstetrics and Gynecology
SARASOTA, Fla., Oct. 21, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell ® medical device and the intravaginal culture ("IVC") procedure...
INVO Bioscience to Exhibit at the 2022 American Society for Reproductive Medicine (ASRM) Congress & Expo
SARASOTA, Fla. and ANAHEIM, Calif., Oct. 17, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable...
Dr. Sue Ellen Carpenter of INVO Bioscience’s Atlanta-based INVO Center – Bloom Fertility – Named Top Doctor by Castle Connolly
SARASOTA, Fla. and ATLANTA, Sept. 22, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell ® medical device and the intravaginal culture...
INVOcell Launched in Malaysia by Advanced Reproductive Centre, Hospital Canselor Tuanku Muhriz
SARASOTA, Fla., Aug. 25, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell ® medical device and the intravaginal culture ("IVC") procedure...
INVO Bioscience Reports Second Quarter 2022 Financial Results
Company to Host Conference Call Today at 4:30pm ET SARASOTA, Fla., Aug. 15, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its...
INVO Bioscience to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022
Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla., Aug. 4, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment...
INVO Bioscience Announces “Get to Know INVOcell” – a Series of Facebook Live Events Supporting Access to Affordable Fertility Treatment
Mark Your Calendars for July 7, 2022, with Dr. Sue Ellen Carpenter of Atlanta-based Bloom Fertility SARASOTA, Fla., July 7, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding...
INVO Signs Distribution Agreement with Onesky Holding Limited for Mainland China
Agreement includes minimum purchase obligations upon product registration and approval SARASOTA, Fla., May 16, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to...
INVO Bioscience Reports First Quarter 2022 Financial Results
Company to Host Conference Call Today at 4:30pm ET SARASOTA, Fla., May 16, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its...